LAVA Therapeutics NV
LVTXDelisted Nov 21, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840748
LAVA Therapeutics NV was delisted on Nov 21, 2025; its insiders filed their last Form 4 on Nov 17, 2025; 21 institutions reported holding it in 13F filings for Q3 2025, worth $16.1M in total; no superinvestor held it.
13F holders, Q3 2022
Institutional positions in LAVA Therapeutics NV as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 13
- −4 vs. Q2 2022
- Shares held
- 7.45M
- −386.5K (−4.9%) vs. Q2 2022
- Total value
- $34.1M
- +$11.2M (+49.3%) vs. Q2 2022
- New holders
- 2
- 2 more added
- Sold out
- 6
- 2 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LVTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 21 | $16.1M |
| Q2 2025 | 19 | $10.6M |
| Q1 2025 | 20 | $10.2M |
| Q4 2024 | 22 | $6.15M |
| Q3 2024 | 21 | $5.99M |
| Q2 2024 | 19 | $6.77M |
| Q1 2024 | 20 | $12.5M |
| Q4 2023 | 14 | $9.22M |
| Q3 2023 | 14 | $8.47M |
| Q2 2023 | 15 | $11.7M |
| Q1 2023 | 19 | $11.2M |
| Q4 2022 | 20 | $26.3M |
| Q3 2022 | 13 | $34.1M |
| Q2 2022 | 17 | $22.8M |
| Q1 2022 | 18 | $35.2M |
| Q4 2021 | 20 | $44.3M |
| Q3 2021 | 19 | $48.6M |
| Q2 2021 | 18 | $95.5M |
| Q1 2021 | 24 | $139.1M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding LAVA Therapeutics NV; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Novo Holdings A/S | 3,327,312 | $15.2M | 0.73% | 00.0% | Unchanged |
| Redmile Group, LLC | 2,816,196 | $12.9M | 0.50% | 00.0% | Unchanged |
| Silverarc Capital Management, LLC | 610,809 | $2.79M | 1.18% | +610,809 | New |
| AXA S.A. | 228,671 | $1.05M | 0.00% | +1,198+0.5% | Added |
| Artal Group S.A. | 200,000 | $914.0K | 0.05% | 00.0% | Unchanged |
| Falcon Edge Capital, LP | 121,193 | $554.0K | 0.07% | 00.0% | Unchanged |
| UBS Oconnor LLC | 75,000 | $343.0K | 0.00% | +75,000 | New |
| Millennium Management LLC | 39,163 | $179.0K | 0.00% | −57,242−59.4% | Reduced |
| Cannell Capital LLC | 17,955 | $82.0K | 0.02% | +13,897+342.5% | Added |
| Geode Capital Management, LLC | 11,124 | $50.0K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 5,000 | $23.0K | 0.00% | −700−12.3% | Reduced |
| TSFG, LLC | 400 | $2.00K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 48 | $0 | 0.00% | 00.0% | Unchanged |
| Nicholas Investment Partners, LP | 0 | $0 | 0.00% | −450,556−100.0% | Sold out |
| Nantahala Capital Management, LLC | 0 | $0 | 0.00% | −322,980−100.0% | Sold out |
| DAFNA Capital Management LLC | 0 | $0 | 0.00% | −128,335−100.0% | Sold out |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −111,993−100.0% | Sold out |
| Bank of New York Mellon Corp | 0 | $0 | 0.00% | −15,173−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −406−100.0% | Sold out |